Abstract
Introduction Hereditary transthyretin-mediated (hATTR) amyloidosis is an underdiagnosed, progressively debilitating disease caused by mutations in the transthyretin (TTR) gene. The V122I variant, one of the most common pathogenic TTR mutations, is found in 3-4% of Black individuals, and has been associated with cardiomyopathy.
Methods To better understand the phenotypic consequences of carrying V122I, we conducted a phenome-wide association study scanning 427 ICD diagnosis codes for association with this variant in Black participants of the UK Biobank (n= 6,062). Significant associations were tested for replication in the Penn Medicine Biobank (n= 5,737) and the Million Veteran Program (n= 82,382).
Results Our analyses discovered a significant association between V122I and polyneuropathy diagnosis (odds ratio = 6.4, 95% confidence interval [CI] = 2.6 to 15.6, P = 4.2 × 10−5) in the UK Biobank,which was replicated in the Penn Medicine Biobank (p=6.0×10−3)) and Million Veteran Program (P= 1.8×10−4)). Polyneuropathy prevalence among V122I carriers was 2.1–9.0% across biobanks. The cumulative incidence of common hATTR amyloidosis manifestations (carpal tunnel syndrome, polyneuropathy, cardiomyopathy, heart failure) was significantly enriched in V122I carriers versus non-carriers (hazard ratio = 2.8, 95% CI = 1.7–4.5, P = 2.6 × 10−5) in the UK Biobank;37.4% of V122I carriers having a diagnosis of any one of these manifestations by age 75.
Conclusions Our findings show that, although the V122I variant is known to be associated with cardiomyopathy, carriers are also at significantly increased risk of developing polyneuropathy. These results also emphasize the underdiagnosis of disease in V122I carriers with a significant proportion of subjects showing phenotypic changes consistent with hATTR. Greater understanding of the manifestations associated with V122I is critical for earlier diagnosis and treatment.
Competing Interest Statement
Conflict of Interest Disclosures: Drs Parker, Erbe, Aldinc, Ticau, Fitzgerald, Vaishnaw, and A.O. Flynn-Carroll are employees and stockholders of Alnylam Pharmaceuticals. Drs Deaton, Ward, and Nioi are employees and stockholders of Alnylam Pharmaceuticals and former employees of Amgen Inc. Dr Hinkle is an employee and stockholder of Alnylam Pharmaceuticals, reports personal fees from 54gene and has a patent US8168775B2 issued. Dr Damrauer reports grants from U.S. Department of Veterans Affairs and RenalytixAI, and personal fees from Calico Labs. Dr Hawkins reports personal fees from Alnylam Pharmaceuticals. Dr Gillmore reports grants and personal fees from Alnylam Pharmaceuticals, and personal fees from Akcea and Eidos Therapeutics. Dr Lynch is an employee with the federal government, Department of Veterans Affairs, and has received grants from the Department of Veteran Affairs. Dr Joseph has received research grants from U.S. Department of Veteran Affairs Office of Research and Development, Novartis, Kowa, Otsuka, and Amgen. Dr Tsao reports grants from U.S. Department of Veteran Affairs Office of Research and Development. Dr Chang is an employee with the federal government, Department of Veterans Affairs, has research funding from the Department of Veteran Affairs, and serves on the scientific advisory board for Arbutus, Inc. Dr Rader reports personal fees from Alnylam Pharmaceuticals, Novartis, and Pfizer. Drs Tcheandjieu, Hull, and Assimes have nothing to disclose.
Funding Statement
Analysis of the UK Biobank data is funded by Alnylam Pharmaceuticals Inc. Dr Damrauer is supported by the U.S. Department of Veterans Affairs (IK2-CX001780). Analysis of the VA Million Veteran Program data is supported by the U.S. Department of Veterans Affairs (I01-BX003362l and VA HSR RES 13-457). This publication does not represent the views of the U.S. Department of Veterans Affairs or the U. S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382) and all participants provided written informed consent to participate in the UK Biobank study. Information about ethics oversight in the UK Biobank can be found at https://www.ukbiobank.ac.uk/ethics/. This research has been conducted using the UK Biobank resource, application no. 26041. The Penn Medicine Biobank research was approved by the Institutional Review Boards of the University of Pennsylvania (Protocol numbers: 808346(CGI), 813913 (PMBB), and 817977 (PMBB tissue). The Million Veterans Program research was approved by the Institutional Review Boards of the Veterans Affairs (Protocol number 19-06 - Genetics of Cardiometabolic Diseased in the VA Population II). Drs Parker, Damrauer, and Tcheandjieu had full access to the UK Biobank, Penn Medicine Biobank, and Million Veteran Program data analyzed in the study, respectively, and take responsibility for the integrity of the data and the accuracy of data analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data is available upon application to the UK Biobank.
